Sherene Loi, MBBS, PhD, FRACP, FAHMS, Peter MacCallum Cancer Centre at the University of Melbourne, Melbourne, Australia, outlines how genomics can inform treatment approaches in triple-negative breast cancer (TNBC). Prof. Loi discusses how mutational status in certain genes can predict treatment responses, such as the well-known breast cancer susceptibility genes, BRCA1 and BRCA2, which predict responsiveness to PARP inhibitors. Other rarer mutations are also under investigation. Additionally, immunohistochemistry testing for HER2 plays a critical role in treatment planning. As new treatments emerge, additional impactful genomic factors are surfacing. This interview took place during the 17th St. Gallen International Breast Cancer Conference.